1. A clinical and molecular review of inverted papilloma of the urinary tract: how to handle?
- Author
-
Ben Vainer, Gregers G. Hermann, and Peter Hjorth Jørgensen
- Subjects
Male ,Microbiology (medical) ,Urologic Neoplasms ,Pathology ,medicine.medical_specialty ,Urinary system ,Loss of Heterozygosity ,Inverted papilloma ,Bioinformatics ,World health ,Pathology and Forensic Medicine ,Urothelial cell carcinoma ,X Chromosome Inactivation ,Atypia ,medicine ,Humans ,Receptor, Fibroblast Growth Factor, Type 3 ,Immunology and Allergy ,Telomere Shortening ,Carcinoma, Transitional Cell ,Papilloma, Inverted ,Urinary bladder ,business.industry ,Microfilament Proteins ,Retrospective cohort study ,General Medicine ,Prognosis ,medicine.disease ,Immunohistochemistry ,Genes, ras ,Ki-67 Antigen ,medicine.anatomical_structure ,Urinary Bladder Neoplasms ,Claudins ,Mutation ,Female ,Carrier Proteins ,business - Abstract
Inverted papilloma (IP) of the urinary tract is classified by the World Health Organisation as a non-invasive urothelial tumour with normal to minimal cytological atypia of the neoplastic cells. During the 1980s, it came under suspicion of having a premalignant or malignant potential and of being concurrent with urothelial cell carcinoma (UCC). This quandary has been proven difficult to solve, due to the fact that IP is very rare and literature mostly consists of case reports with varying levels of information, making strong meta-analyses problematic. New immunohistochemical techniques and genetic approaches are more frequently being used in the attempt to achieve better classifications, prognosis and treatment of lesions hereunder IP. This review will, in our awareness, be the first to combine the knowledge from retrospective studies with these new approaches for determining a possible premalignant potential and concurrency with UCC and subsequently outline a recommendation for follow-up.
- Published
- 2015
- Full Text
- View/download PDF